Jacobs Levy Equity Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-33,530	Closed	-$165K	–	1142
2021 Q3	$165K	Sell	33,530 -17,173	-34%	-$83.4K	﹤0.01%	999
2021 Q2	$268K	Sell	50,703 -249,543	-83%	-$1.29M	﹤0.01%	943
2021 Q1	$1.44M	Buy	300,246 +78,456	+35%	+$410K	0.01%	657
2020 Q4	$960K	Buy	221,790 +45,800	+26%	+$196K	0.01%	733
2020 Q3	$725K	Buy	175,990 +49,287	+39%	+$191K	0.01%	720
2020 Q2	$324K	Sell	126,703 -37,653	-23%	-$111K	﹤0.01%	871
2020 Q1	$475K	Buy	164,356 +14,377	+10%	+$64.4K	0.01%	764
2019 Q4	$568K	Buy	149,979 +71,379	+91%	+$342K	0.01%	770
2019 Q3	$402K	Buy	+78,600	New	+$485K	﹤0.01%	748
2015 Q2	–	Sell	-19,300	Closed	-$338K	–	880
2015 Q1	$338K	Buy	+19,300	New	+$331K	0.01%	632

Jacobs Levy Equity Management's ADMS Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 33,530 shares — an estimated $165K sold.

Jacobs Levy Equity Management first reported a position in ADMS in Q1 2015 and held it in 10 quarters. The position peaked at $1.44M in Q1 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 33,530 Adamas Pharmaceuticals shares in Q4 2021, an estimated $165K.
Jacobs Levy Equity Management first reported a position in Adamas Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Jacobs Levy Equity Management's Adamas Pharmaceuticals position peaked at $1.44M in Q1 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.